表紙
市場調査レポート

軟部組織肉腫:パイプライン製品の分析

Soft Tissue Sarcoma - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 213064
出版日 ページ情報 英文 470 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
軟部組織肉腫:パイプライン製品の分析 Soft Tissue Sarcoma - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 470 Pages
概要

軟部組織肉腫とは、人体の軟部組織より発症するがん性腫瘍(悪性腫瘍)を指します。主な症状として、目立つ大きさの瘤や腫脹、胃・腸の閉塞、(腫瘍が下腹部や消化管にある場合は)胃腸出血、疼痛などが挙げられます。主な疾病素質には、放射線被爆や化学薬品、遺伝的症候群などが含まれています。主な治療法には、化学療法や放射線治療などがあります。

当レポートでは、世界各国での軟部組織肉腫治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

軟部組織肉腫の概要

治療薬の開発

  • 軟部組織肉腫向けパイプライン製品:概要
  • 軟部組織肉腫向けパイプライン製品:比較分析

各企業で開発中の軟部組織肉腫治療薬

大学/研究機関で研究中の軟部組織肉腫治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

軟部組織肉腫治療薬:開発中の製品の一覧(企業別)

軟部組織肉腫治療薬:研究中の製品の一覧(大学/研究機関別)

軟部組織肉腫治療薬の開発に従事している企業

  • Amgen Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Cell Therapeutics, Inc.
  • Exelixis, Inc.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Celgene Corporation
  • Bayer AG
  • EntreMed, Inc.
  • Oncolytics Biotech Inc.
  • Topotarget A/S
  • CytRx Corporation
  • Threshold Pharmaceuticals, Inc.
  • MabVax Therapeutics, Inc.
  • Nanobiotix SA
  • Morphotek, Inc.
  • GP Pharm, S.A.
  • MolMed S.p.A.
  • Pharma Mar, S.A.
  • TRACON Pharmaceuticals, Inc.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd
  • Recombio
  • Polaris Group
  • Karyopharm Therapeutics, Inc.
  • Activartis Biotech GmbH

軟部組織肉腫:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • リダフォロリムス
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • アルドキソルビシン
  • TH-302
  • トラベクテジン
  • N-glycolyl-GM3/超小型プロテオリポソームワクチン
  • レゴラフェニブ
  • sabarubicin
  • リンゴ酸スニチニブ
  • ブロスタリシン
  • ENMD-2076
  • パノビノスタット
  • ganitumab
  • ベリノスタット
  • エベロリムス
  • カボザンチニブ sリンゴ酸
  • NGR-hTNF
  • pelareorep
  • ontuxizumab
  • Angiotensin 1-7
  • 肉腫ワクチン
  • 塩酸パゾパニブ
  • トラベクテジン
  • ドキソブリシン・リポソーマ
  • AL-3818
  • olaratumab
  • アルブミン結合パクリタキセル
  • ニューカッスル病ウイルス:HUJ腫瘍溶解性ウイルス
  • ONCOS-102
  • NBTXR-3
  • TRC-105
  • AV0-113
  • KPT-330
  • TNF-PEG 20
  • NOV-110501
  • NBTX-TOPO
  • NBTXR-3

軟部組織肉腫治療薬:パイプライン製品の最新動向

軟部組織肉腫治療薬:開発が休止状態の製品

軟部組織肉腫治療薬:開発が中止された製品

軟部組織肉腫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7316IDB

Summary

Global Markets Direct's, 'Soft Tissue Sarcoma - Pipeline Review, H2 2015', provides an overview of the Soft Tissue Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Soft Tissue Sarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Soft Tissue Sarcoma - Overview
    • Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis
  • Soft Tissue Sarcoma - Therapeutics under Development by Companies
  • Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes
  • Soft Tissue Sarcoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Soft Tissue Sarcoma - Products under Development by Companies
  • Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes
  • Soft Tissue Sarcoma - Companies Involved in Therapeutics Development
    • A. Menarini Industrie Farmaceutiche Riunite Srl
    • Advanced Proteome Therapeutics Corporation
    • Advenchen Laboratories, LLC
    • Altor BioScience Corporation
    • Amgen Inc.
    • Arog Pharmaceuticals, Inc.
    • Bayer AG
    • Bellicum Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • CASI Pharmaceuticals Inc.
    • Celgene Corporation
    • Cell Medica Limited
    • Cellceutix Corporation
    • Cellectar Biosciences, Inc.
    • CytRx Corporation
    • Daiichi Sankyo Company, Limited
    • Double Bond Pharmaceutical International AB
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • EpiZyme, Inc.
    • Exelixis, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gem Pharmaceuticals, LLC
    • GlaxoSmithKline Plc
    • Immune Design Corp.
    • Karyopharm Therapeutics, Inc.
    • Loxo Oncology, Inc.
    • Lytix Biopharma AS
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Merrimack Pharmaceuticals, Inc.
    • Mirati Therapeutics Inc.
    • MolMed S.p.A.
    • Morphotek, Inc.
    • Northwest Biotherapeutics, Inc.
    • Novartis AG
    • Noxxon Pharma AG
    • OncoTherapy Science, Inc.
    • Onxeo SA
    • Pfizer Inc.
    • Pharma Mar, S.A.
    • Philogen S.p.A.
    • Plexxikon Inc.
    • Polaris Pharmaceuticals, Inc.
    • Recombio S.L
    • Rigontec GmbH
    • Sanofi
    • Shionogi & Co., Ltd.
    • Siena Biotech S.p.A.
    • Sigma-Tau S.p.A.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Targovax AS
    • Threshold Pharmaceuticals, Inc.
    • TRACON Pharmaceuticals, Inc.
    • Vicore Pharma AB
  • Soft Tissue Sarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afatinib dimaleate - Drug Profile
    • AL-3818 - Drug Profile
    • aldoxorubicin hydrochloride - Drug Profile
    • ALT-836 - Drug Profile
    • APC-103 - Drug Profile
    • belinostat - Drug Profile
    • BI-853520 - Drug Profile
    • C-21 - Drug Profile
    • cabazitaxel - Drug Profile
    • cabozantinib s-malate - Drug Profile
    • cancer vaccine - Drug Profile
    • Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
    • Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
    • celyvir - Drug Profile
    • CMD-003 - Drug Profile
    • crenolanib besylate - Drug Profile
    • DCVax-Direct - Drug Profile
    • Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
    • Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile
    • DSR-6434 - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • efatutazone - Drug Profile
    • emactuzumab - Drug Profile
    • ENMD-2076 - Drug Profile
    • eribulin mesylate - Drug Profile
    • everolimus - Drug Profile
    • evofosfamide - Drug Profile
    • Fibromun - Drug Profile
    • G-100 - Drug Profile
    • GPX-150 - Drug Profile
    • GSK-3174998 - Drug Profile
    • HDM-201 - Drug Profile
    • I131-CLR1404 - Drug Profile
    • ID-LV305 + ID-G305 - Drug Profile
    • ImOl-100 - Drug Profile
    • irinotecan hydrochloride - Drug Profile
    • KM-3174 - Drug Profile
    • KRA-0008 - Drug Profile
    • LK-3 - Drug Profile
    • LOXO-101 - Drug Profile
    • LTX-315 - Drug Profile
    • LV-305 - Drug Profile
    • MAT-303 - Drug Profile
    • mocetinostat - Drug Profile
    • MVXONCO-1 - Drug Profile
    • NGR-hTNF - Drug Profile
    • NOV-110501 - Drug Profile
    • NOXS-93 - Drug Profile
    • olaratumab - Drug Profile
    • ONCOS-102 - Drug Profile
    • ontuxizumab - Drug Profile
    • OTSA-101 - Drug Profile
    • paclitaxel albumin bound - Drug Profile
    • palbociclib - Drug Profile
    • panobinostat - Drug Profile
    • pazopanib hydrochloride - Drug Profile
    • pembrolizumab - Drug Profile
    • Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
    • PF-03084014 - Drug Profile
    • PLX-7486 - Drug Profile
    • regorafenib - Drug Profile
    • ribociclib - Drug Profile
    • roneparstat - Drug Profile
    • S-588410 - Drug Profile
    • SA-083 - Drug Profile
    • sabarubicin - Drug Profile
    • selinexor - Drug Profile
    • SEN-461 - Drug Profile
    • talimogene laherparepvec - Drug Profile
    • tazemetostat - Drug Profile
    • TNF-PEG 20 - Drug Profile
    • trabectedin - Drug Profile
    • TRC-105 - Drug Profile
    • Vaccine for Soft Tissue Sarcoma - Drug Profile
    • vorinostat - Drug Profile
  • Soft Tissue Sarcoma - Recent Pipeline Updates
  • Soft Tissue Sarcoma - Dormant Projects
  • Soft Tissue Sarcoma - Discontinued Products
  • Soft Tissue Sarcoma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Soft Tissue Sarcoma, H2 2015
  • Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Soft Tissue Sarcoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Altor BioScience Corporation, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Amgen Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Bayer AG, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Soft Tissue Sarcoma - Pipeline by CASI Pharmaceuticals Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Celgene Corporation, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Cell Medica Limited, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Cellceutix Corporation, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Cellectar Biosciences, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by CytRx Corporation, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Eisai Co., Ltd., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Eli Lilly and Company, H2 2015
  • Soft Tissue Sarcoma - Pipeline by EpiZyme, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Exelixis, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Gem Pharmaceuticals, LLC, H2 2015
  • Soft Tissue Sarcoma - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Immune Design Corp., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Loxo Oncology, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Lytix Biopharma AS, H2 2015
  • Soft Tissue Sarcoma - Pipeline by MedImmune, LLC, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Merck & Co., Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Mirati Therapeutics Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by MolMed S.p.A., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Morphotek, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Northwest Biotherapeutics, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Novartis AG, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Noxxon Pharma AG, H2 2015
  • Soft Tissue Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Onxeo SA, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Pfizer Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Pharma Mar, S.A., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Philogen S.p.A., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Plexxikon Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Recombio S.L, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Rigontec GmbH, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Sanofi, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Siena Biotech S.p.A., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Sigma-Tau S.p.A., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Targovax AS, H2 2015
  • Soft Tissue Sarcoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
  • Soft Tissue Sarcoma - Pipeline by Vicore Pharma AB, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Soft Tissue Sarcoma Therapeutics - Recent Pipeline Updates, H2 2015
  • Soft Tissue Sarcoma - Dormant Projects, H2 2015
  • Soft Tissue Sarcoma - Dormant Projects (Contd..1), H2 2015
  • Soft Tissue Sarcoma - Dormant Projects (Contd..2), H2 2015
  • Soft Tissue Sarcoma - Dormant Projects (Contd..3), H2 2015
  • Soft Tissue Sarcoma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Soft Tissue Sarcoma, H2 2015
  • Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top